Cardium wins patent suit against Boston Scientific, Arch Development

By Elaine Rigoli

Tampa, Fla., May 11 - Cardium Therapeutics, Inc. announced that the U.S. Court of Appeals for the Federal Circuit has ruled in Cardium's favor in a case involving Arch Development Corp. and Arch's licensee, Boston Scientific Corp.

The appeal was brought by Arch and Boston Scientific after the Board of Patent Appeals and Interferences had ruled against them with respect to a series of patents and patent applications related to angiogenic treatments for coronary heart disease, including myocardial ischemia and angina, according to a news release.

"The completion of these important reviews of our intellectual property position, and consistent decisions in our favor, serves to underscore the value of our patent portfolio, which we believe reflects a best-in-class approach to the treatment of coronary heart disease," Cardium chief business officer and general counsel Tyler M. Dylan said in the release.

Cardium, headquartered in San Diego, is a medical technology company focused on the development of therapeutic products for the interventional cardiology market.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.